466 related articles for article (PubMed ID: 22310613)
41. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch.
Higgins R; Lowe D; Hathaway M; Williams C; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Daga S; Edey M; Zehnder D; Briggs D
Transplantation; 2011 Oct; 92(8):900-6. PubMed ID: 21968524
[TBL] [Abstract][Full Text] [Related]
42. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
43. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching.
Nikaein A; Backman L; Jennings L; Levy MF; Goldstein R; Gonwa T; Stone MJ; Klintmalm G
Transplantation; 1994 Oct; 58(7):786-92. PubMed ID: 7940711
[TBL] [Abstract][Full Text] [Related]
44. Flow cytometric evaluation of pregnancy-induced anti-donor immunization.
Ayna TK; Ciftci HS; Tozkir H; Sagiroglu T; Isitmangil G; Gurtekin B; Gurtekin M
Transplant Proc; 2012; 44(6):1656-9. PubMed ID: 22841238
[TBL] [Abstract][Full Text] [Related]
45. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
46. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
47. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
Kimball PM; King A
Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
[TBL] [Abstract][Full Text] [Related]
48. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
Aubert V; Venetz JP; Pantaleo G; Pascual M
Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
50. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
51. Low median fluorescence intensity could be a nonsafety concept of immunologic risk evaluation in patients with shared molecular eplets in kidney transplantation.
Bosch A; Llorente S; Diaz JA; Salgado G; López M; Boix F; López-Hernández R; González-Soriano MJ; Campillo JA; Moya-Quiles MR; Perez-Lopez N; Minguela A; Jimeno L; Alvarez-López MR; Muro M
Hum Immunol; 2012 May; 73(5):522-5. PubMed ID: 22425738
[TBL] [Abstract][Full Text] [Related]
52. [Indications for apheresis in kidney transplant recipients: apheresis in the hyperimmune patient].
Busnach G; Di Leo L
G Ital Nefrol; 2012; 29 Suppl 54():S22-6. PubMed ID: 22388825
[TBL] [Abstract][Full Text] [Related]
53. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
[TBL] [Abstract][Full Text] [Related]
54. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
55. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
56. Kidney transplantation, the Halifax experience.
Belitsky P; MacDonald AS; Lawen J; McAlister V; Bitter-Suermann H; Kiberd B; West K; Sketris I
Clin Transpl; 1996; ():231-40. PubMed ID: 9286572
[TBL] [Abstract][Full Text] [Related]
57. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
Billen EV; Christiaans MH; van den Berg-Loonen EM
Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
[TBL] [Abstract][Full Text] [Related]
58. Early findings of prospective anti-HLA donor specific antibodies monitoring study in pancreas transplantation: Indiana University Health Experience.
Mujtaba MA; Fridell JA; Higgins N; Sharfuddin AA; Yaqub MS; Kandula P; Chen J; Mishler DP; Lobashevsky A; Book B; Powelson J; Taber TE
Clin Transplant; 2012; 26(5):E492-9. PubMed ID: 22938159
[TBL] [Abstract][Full Text] [Related]
59. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
[TBL] [Abstract][Full Text] [Related]
60. Combined liver and kidney transplantation in a highly sensitized and positively cross-matched patient.
Alqurashi S; Alsayyari AA; Abdullah K; Alwan A; Hajeer AH
Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):757-60. PubMed ID: 21743223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
